Correlation between Extreme Drug Resistance Assay and Response to Primary Paclitaxel and Cisplatin in Patients with Epithelial Ovarian Cancer

By Eltabbakh G.H.   Piver M.S.   Hempling R.E.   Recio F.O.   Lele S.B.   Marchetti D.L.   Baker T.R.   Blumenson L.E.  

Gynecologic Oncology, Vol. 70, Iss. 3, 1998-09 ,pp. : 392-397

Elsevier

Access to resources Recommend Favorite

Salvage chemotherapy With CPT-11 for recurrent meningioma

By Chamberlain Marc   Tsao-Wei Denice   Groshen Susan  

Journal of Neuro-Oncology, Vol. 78, Iss. 3, 2006-07 ,pp. : 271-276

Springer Publishing Company

Access to resources Recommend Favorite

Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay

By Mehta R.S.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 3, 2001-04 ,pp. : 225-237

Springer Publishing Company

Access to resources Recommend Favorite

Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors

By Feun Lynn   Marini Angela   Landy Howard   Markoe Arnold   Heros Deborah   Robles Carlos   Herrera Cristina   Savaraj Niramol  

Journal of Neuro-Oncology, Vol. 82, Iss. 2, 2007-04 ,pp. : 177-181

Springer Publishing Company

Access to resources Recommend Favorite

Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer

By Ohara Tatsuru   Kobayashi Yoichi   Yoshida Ayako   Yoshioka Norihito   Yahagi Namiko   Kondo Haruhiro   Tozawa Akiko   Kiguchi Kazushige   Suzuki Nao  

International Journal of Clinical Oncology, Vol. 18, Iss. 6, 2013-12 ,pp. : 1102-1106

Springer Publishing Company

Access to resources Recommend Favorite